Các bài viết có thể truy cập công khai - Sandro PignataTìm hiểu thêm
Không có ở bất kỳ nơi nào: 9
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
S Pignata, G Scambia, D Katsaros, C Gallo, E Pujade-Lauraine, ...
The Lancet Oncology 15 (4), 396-405, 2014
Các cơ quan ủy nhiệm: US National Institutes of Health
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
S Pignata, D Lorusso, F Joly, C Gallo, N Colombo, C Sessa, A Bamias, ...
The Lancet Oncology 22 (2), 267-276, 2021
Các cơ quan ủy nhiệm: AIRC Foundation for Cancer Research in Italy
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer: A Multicentre Italian Trial in Ovarian cancer …
S Pignata, E Breda, G Scambia, C Pisano, V Zagonel, D Lorusso, ...
Critical reviews in oncology/hematology 66 (3), 229-236, 2008
Các cơ quan ủy nhiệm: US National Institutes of Health
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience
G Mangili, C Sigismondi, D Lorusso, G Cormio, P Scollo, R Vigano, ...
Gynecologic oncology 121 (2), 280-284, 2011
Các cơ quan ủy nhiệm: US National Institutes of Health
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study
S Pignata, G Ferrandina, G Scarfone, P Scollo, F Odicino, G Cormio, ...
Critical reviews in oncology/hematology 71 (3), 233-241, 2009
Các cơ quan ủy nhiệm: US National Institutes of Health
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy
S Pignata, F Amant, G Scambia, R Sorio, E Breda, W Rasch, K Hernes, ...
Cancer chemotherapy and pharmacology 68, 1347-1353, 2011
Các cơ quan ủy nhiệm: Research Foundation (Flanders)
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial
L Musacchio, M Turinetto, L Arenare, M Bartoletti, D Califano, V Tuninetti, ...
Gynecologic Oncology 172, 72-77, 2023
Các cơ quan ủy nhiệm: Government of Italy, AIRC Foundation for Cancer Research in Italy
The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature
J Ventriglia, A Passarelli, C Pisano, SC Cecere, S Rossetti, F Feroce, ...
Critical Reviews in Oncology/Hematology 188, 104036, 2023
Các cơ quan ủy nhiệm: US National Institutes of Health
Endometrial cancer in the elderly: characteristics, prognostic and risk factors, and treatment options
M Forte, SC Cecere, M Di Napoli, J Ventriglia, R Tambaro, S Rossetti, ...
Critical Reviews in Oncology/Hematology, 104533, 2024
Các cơ quan ủy nhiệm: Forskningsrådet för arbetsliv, hälsa och välfärd
Có tại một số nơi: 84
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ...
New England Journal of Medicine 381 (25), 2416-2428, 2019
Các cơ quan ủy nhiệm: German Research Foundation
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
Các cơ quan ủy nhiệm: US Department of Defense, US National Institutes of Health, Cancer Research …
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ...
International Journal of Gynecological Cancer 29 (4), 728-760, 2019
Các cơ quan ủy nhiệm: US Department of Defense
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
UA Matulonis, R Shapira-Frommer, AD Santin, AS Lisyanskaya, S Pignata, ...
Annals of Oncology 30 (7), 1080-1087, 2019
Các cơ quan ủy nhiệm: National Institute for Health Research, UK
Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39)
KN Moore, M Bookman, J Sehouli, A Miller, C Anderson, G Scambia, ...
Journal of Clinical Oncology 39 (17), 1842-1855, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health
Clinical trials in recurrent ovarian cancer
M Friedlander, E Trimble, A Tinker, D Alberts, E Avall-Lundqvist, M Brady, ...
International Journal of Gynecological Cancer 21 (4), 771-775, 2011
Các cơ quan ủy nhiệm: US National Institutes of Health
Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ...
Journal of Clinical Oncology 41 (18), 3339-3351, 2023
Các cơ quan ủy nhiệm: US National Institutes of Health
Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study
UA Matulonis, D Lorusso, A Oaknin, S Pignata, A Dean, H Denys, ...
Journal of clinical oncology 41 (13), 2436-2445, 2023
Các cơ quan ủy nhiệm: US National Institutes of Health, Health Research Board, Ireland
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
A Vecchione, B Belletti, F Lovat, S Volinia, G Chiappetta, S Giglio, ...
Proceedings of the National Academy of Sciences 110 (24), 9845-9850, 2013
Các cơ quan ủy nhiệm: US National Institutes of Health
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase …
S Pignata, D Lorusso, G Scambia, D Sambataro, S Tamberi, S Cinieri, ...
The Lancet Oncology 16 (5), 561-568, 2015
Các cơ quan ủy nhiệm: US National Institutes of Health
Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary
G Mangili, J Ottolina, A Gadducci, G Giorda, E Breda, A Savarese, ...
British journal of cancer 109 (1), 29-34, 2013
Các cơ quan ủy nhiệm: US National Institutes of Health
Chương trình máy tính sẽ tự động xác định thông tin xuất bản và thông tin về nhà tài trợ